Europe Single-use Bioreactors Market Set to Reach $3.34 Billion by 2030

[Redding, California, February 23, 2024] - Meticulous Research®, a globally recognized leader in market research, has unveiled its latest report titled 'Europe Single-use Bioreactors Market by Product [Systems, Media Bags (2D, 3D), Filtration Assemblies], Type [Stirred Tank, Wave Induced], Cell [Mammalian, Bacterial, Yeast], Application [Commercial (Mab, Vaccine), Research], End User - Forecast to 2030.'

Download Free Research PDF @ https://www.meticulousresearch.com/download-sample-report/cp_id=5552

The report forecasts that the Europe single-use bioreactors market will soar to $3.34 billion by 2030, showcasing a robust CAGR of 15.3%. This surge is fueled by the escalating adoption of disposable technologies in the pharmaceutical and biotechnology sectors, expansions in biopharmaceutical plant capacities, augmented pharmaceutical R&D investments, the burgeoning acceptance of biosimilars, and the mounting prevalence of chronic ailments among the aging populace.

Future Outlook of the Europe Single-use Bioreactors Market:
The European single-use bioreactors market is meticulously segmented by Product {Single-use Bioreactor Systems (Upto 10L, 11L-500L, 501L-1000L, and above 1001L), Media Bags (2D, 3D, and Linear), Filtration Assemblies, and Other Products}, Type (Stirred-Tank, Wave-Induced, and Other Types), Cell Type (Mammalian Cells, Bacterial Cells, Yeast Cells, and Other Cell Types), Application [Commercial Bioproduction (mAb Production, Vaccine Production, Therapeutic Protein Production, and Cell and Gene Therapy) Research Bioproduction], End User {Pharmaceutical and Biopharmaceutical Companies; Contract Research Organizations and Contract Development and Manufacturing Organizations (CDMO); and Academic and Research Institutes}, and Geography.

The study delves into industry competitors, meticulously analyzing their country-level market share and growth strategies.

Browse in depth @ https://www.meticulousresearch.com/product/europe-single-use-bioreactors-market-5552

Based on product, the European single-use bioreactor market is classified into single-use bioreactor systems, media bags, filtration assemblies, and other products. In 2023, the single-use bioreactor systems segment is poised to dominate the market, primarily due to their inherent advantages such as reduced cleaning requirements, heightened flexibility, a smaller footprint, diminished capital investment, and minimized risk of cross-contamination. Furthermore, the vendors' focus on large-scale bio-manufacturing bolsters this growth, alongside the surging demand from biopharmaceutical companies aiming to curtail excessive costs associated with traditional instruments.

Based on type, the stirred-tank bioreactors segment is anticipated to seize the lion's share of the market in 2023. The increased utilization of stirred-tank bioreactors in CHO cell lines & suspension culture, coupled with their suitability for large volume bio-production and contemporary design features compared to traditional counterparts, propels this segment's dominance.

Based on Cell type, the mammalian cells segment is projected to command the largest market share in 2023. Mammalian cells are widely acknowledged as an experimental model of choice, thus witnessing extensive adoption in commercial & research bioproduction endeavors, including the development of intricate biomolecules like monoclonal antibodies and therapeutic proteins, as well as their extensive utilization in clinical research.

Speck to our analyst @ https://www.meticulousresearch.com/speak-to-analyst/cp_id=5552

Based on application, the commercial bioproduction segment is expected to reign supreme in 2023. This dominance is attributed to the burgeoning production of biosimilars, the escalating incidence of genetic & rare diseases, and governmental backing for vaccine production and immunization initiatives.

Based on end user, the contract development and manufacturing organizations (CDMOs) and contract research organizations (CROs) segment is poised to register the highest CAGR during the forecast period. This growth trajectory is underpinned by the pharmaceutical and biopharmaceutical companies' outsourcing activities to CDMOs, coupled with key players' predilection for inorganic growth strategies and the expansion endeavors of CDMOs, exemplified by Viralgen VC's inauguration of a new manufacturing facility in Basque, Italy, in July 2021, dedicated to adeno-associated virus gene therapy production.

Geographic Review
The report conducts an in-depth analysis of major geographies, with a comprehensive assessment of European countries including Germany, France, the U.K., Italy, Spain, Switzerland, Ireland, Denmark, Belgium, and the Rest of Europe. In 2023, Germany is poised to claim the largest share of the European single-use bioreactors market, buoyed by robust drug sales, governmental and regulatory backing to promote biopharmaceutical usage across diverse health indications, and the expansive endeavors of numerous companies in bolstering their manufacturing capacities and operations.

Quick Buy - Europe Single-use Bioreactors Market - Opportunity Analysis and Industry Forecast (2023-2030), Research Report: https://www.meticulousresearch.com/Checkout/65611519

Key Players
Key players profiled in the European single-use bioreactors market report include Merck KGaA (Germany), Danaher Corporation (U.S.), Sartorius AG (Germany), Thermo Fisher Scientific Inc. (U.S.), Eppendorf AG (Germany), Solaris Biotechnology srl (Italy), Cellexus International Ltd. (U.K.) CESCO Bioengineering Co., Ltd. (Taiwan), PBS Biotech, Inc. (U.S.), Solida Biotech GmbH (Germany), and Infors AG (Switzerland).

Contact:
Mr. Khushal Bombe
Meticulous Market Research Inc.
1267 Willis St, Ste 200 Redding,
California, 96001, U.S.
USA: +1-646-781-8004
Europe : +44-203-868-8738
APAC: +91 744-7780008
Email- sales@meticulousresearch.com
Visit Our Website: https://www.meticulousresearch.com/
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research

We are the trusted research partners for leading businesses around the world, providing market intelligence focused towards building revenue transformation strategies. Our research is used by Fortune 500 organizations to attain success by scouting next generation revenue opportunities well ahead of their competition.

This release was published on openPR.